AstraZeneca announced the formal establishment of AstraZeneca Cell Technology Co., Ltd. in Lingang, Shanghai, to improve the company's end-to-end layout of cell therapy from R&D to commercial production in China, and support supply to the Chinese and Asian markets. At the same time, the company officially launched a new drug development and supply building upgrade project to build a production and supply base in Wuxi. With an investment of nearly 200 million yuan, the project will enhance the production and global marketing supply capacity of innovative cardiovascular drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.